Search

Your search keyword '"Krikke, Maaike"' showing total 9 results
Start Over Author "Krikke, Maaike"
9 results on '"Krikke, Maaike"'

3. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients

Author

Krikke, Maaike, Tesselaar, Kiki, van den Berk, Guido E.L., Otto, Sigrid A., Freriks, Laura H., van Lelyveld, Steven F.L., Visseren, Frank J.L., Hoepelman, Andy I.M., Arends, Joop E., Krikke, Maaike, Tesselaar, Kiki, van den Berk, Guido E.L., Otto, Sigrid A., Freriks, Laura H., van Lelyveld, Steven F.L., Visseren, Frank J.L., Hoepelman, Andy I.M., and Arends, Joop E.

Published
2018

4. The effect of switching protease inhibitors to raltegravir on endothelial function, in HIV-infected patients

Author

MS Infectieziekten, CTI Borghans, CTI, Interne Geneeskunde Vasculaire, Circulatory Health, Infection & Immunity, MS Interne Geneeskunde, Krikke, Maaike, Tesselaar, Kiki, van den Berk, Guido E.L., Otto, Sigrid A., Freriks, Laura H., van Lelyveld, Steven F.L., Visseren, Frank J.L., Hoepelman, Andy I.M., Arends, Joop E., MS Infectieziekten, CTI Borghans, CTI, Interne Geneeskunde Vasculaire, Circulatory Health, Infection & Immunity, MS Interne Geneeskunde, Krikke, Maaike, Tesselaar, Kiki, van den Berk, Guido E.L., Otto, Sigrid A., Freriks, Laura H., van Lelyveld, Steven F.L., Visseren, Frank J.L., Hoepelman, Andy I.M., and Arends, Joop E.

Published
2018

5. Maraviroc Intensification Improves Endothelial Function in Abacavir-Treated Patients, an Open-Label Randomized Cross-Over Pilot Study

Author

Infection & Immunity, CTI Borghans, MS Interne Geneeskunde, CTI, Interne Geneeskunde Vasculaire, Circulatory Health, MS Infectieziekten, Krikke, Maaike, Tesselaar , Kiki, Arends, Joop E, Drylewicz, Julia, Otto, Sigrid A, van Lelyveld, Steven F L, Visseren, Frank J L, Hoepelman, Andy I M, Infection & Immunity, CTI Borghans, MS Interne Geneeskunde, CTI, Interne Geneeskunde Vasculaire, Circulatory Health, MS Infectieziekten, Krikke, Maaike, Tesselaar , Kiki, Arends, Joop E, Drylewicz, Julia, Otto, Sigrid A, van Lelyveld, Steven F L, Visseren, Frank J L, and Hoepelman, Andy I M

Published
2016

6. Maraviroc intensification of cART in patients with suboptimal immunological recovery : A 48-week, placebo-controlled randomized trial

Author

van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M J, Nijhuis, Monique, Borghans, José A M, Tesselaar, Kiki, Hoepelman, Andy I M, van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M J, Nijhuis, Monique, Borghans, José A M, Tesselaar, Kiki, and Hoepelman, Andy I M

Published
2015

7. Maraviroc intensification of cART in patients with suboptimal immunological recovery: A 48-week, placebo-controlled randomized trial

Author

MS Infectieziekten, MS Interne Geneeskunde, CTI Borghans, Infection & Immunity, CTI, MMB Medische Staf, MMB Research line 3a, van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M J, Nijhuis, Monique, Borghans, José A M, Tesselaar, Kiki, Hoepelman, Andy I M, MS Infectieziekten, MS Interne Geneeskunde, CTI Borghans, Infection & Immunity, CTI, MMB Medische Staf, MMB Research line 3a, van Lelyveld, Steven F. L., Drylewicz, Julia, Krikke, Maaike, Veel, Ellen M., Otto, Sigrid A., Richter, Clemens, Soetekouw, Robin, Prins, Jan M., Brinkman, Kees, Mulder, Jan Willem, Kroon, Frank, Middel, Ananja, Symons, Jori, Wensing, Annemarie M J, Nijhuis, Monique, Borghans, José A M, Tesselaar, Kiki, and Hoepelman, Andy I M

Published
2015

8. Maraviroc Intensification of cART in Patients with Suboptimal Immunological Recovery: A 48-Week, Placebo-Controlled Randomized Trial.

Author

van Lelyveld SF, Drylewicz J, Krikke M, Veel EM, Otto SA, Richter C, Soetekouw R, Prins JM, Brinkman K, Mulder JW, Kroon F, Middel A, Symons J, Wensing AM, Nijhuis M, Borghans JA, Tesselaar K, and Hoepelman AI

Subjects
Adult, CCR5 Receptor Antagonists therapeutic use, CD4-CD8 Ratio, CD4-Positive T-Lymphocytes drug effects, CD4-Positive T-Lymphocytes immunology, CD4-Positive T-Lymphocytes metabolism, CD8-Positive T-Lymphocytes drug effects, CD8-Positive T-Lymphocytes immunology, CD8-Positive T-Lymphocytes metabolism, Double-Blind Method, Female, HIV Fusion Inhibitors therapeutic use, HIV Infections virology, HIV-1 physiology, Humans, Lymphocyte Count, Male, Maraviroc, Middle Aged, Receptors, CCR5 metabolism, Time Factors, Treatment Outcome, Anti-HIV Agents therapeutic use, Antiretroviral Therapy, Highly Active, Cyclohexanes therapeutic use, HIV Infections drug therapy, HIV-1 drug effects, Triazoles therapeutic use
Abstract

Objective: The immunomodulatory effects of the CCR5-antagonist maraviroc might be beneficial in patients with a suboptimal immunological response, but results of different cART (combination antiretroviral therapy) intensification studies are conflicting. Therefore, we performed a 48-week placebo-controlled trial to determine the effect of maraviroc intensification on CD4+ T-cell counts and immune activation in these patients., Design: Double-blind, placebo-controlled, randomized trial., Methods: Major inclusion criteria were 1. CD4+ T-cell count <350 cells/μL while at least two years on cART or CD4+ T-cell count <200 cells/μL while at least one year on cART, and 2. viral suppression for at least the previous 6 months. HIV-infected patients were randomized to add maraviroc (41 patients) or placebo (44 patients) to their cART regimen for 48 weeks. Changes in CD4+ T-cell counts (primary endpoint) and other immunological parameters were modeled using linear mixed effects models., Results: No significant differences for the modelled increase in CD4+ T-cell count (placebo 15.3 CD4+ T cells/μL (95% confidence interval (CI) [1.0, 29.5] versus maraviroc arm 22.9 CD4+ T cells/μL (95% CI [7.4, 38.5] p = 0.51) or alterations in the expression of markers for T-cell activation, proliferation and microbial translocation were found between the arms. However, maraviroc intensification did increase the percentage of CCR5 expressing CD4+ and CD8+ T-cells, and the plasma levels of the CCR5 ligand MIP-1β. In contrast, the percentage of ex-vivo apoptotic CD8+ and CD4+ T-cells decreased in the maraviroc arm., Conclusions: Maraviroc intensification of cART did not increase CD4+ T-cell restoration or decrease immune activation as compared to placebo. However, ex-vivo T-cell apoptosis was decreased in the maraviroc arm., Trial Registration: ClinicalTrials.gov NCT00875368.

Published
2015
Full Text
View/download PDF

9. [Addison's disease, primary adrenal insufficiency in adults].

Author

Krikke M, ten Wolde M, and Smit N

Subjects
Addison Disease blood, Addison Disease drug therapy, Addison Disease immunology, Adrenal Glands immunology, Adrenal Glands physiopathology, Adrenocorticotropic Hormone blood, Adult, Female, Humans, Hydrocortisone, Male, Addison Disease diagnosis, Adrenal Cortex Function Tests, Adrenocorticotropic Hormone deficiency, Glucocorticoids therapeutic use
Abstract

Adrenal insufficiency is a rare but fatal disease if left unrecognized. Symptoms often mimic more prevalent diseases. We discuss three patients with primary adrenal insufficiency. These cases illustrate that presenting symptoms such as syncope, nausea, vomiting, weight loss and hypoglycemia are often non-specific and, therefore, often not immediately recognized. When an adrenal crisis is suspected, glucocorticoids should be given promptly. The symptoms are caused by insufficient production of adrenal hormones due to destruction of the adrenal glands by auto-immune adrenalitis. An ACTH stimulation test should confirm the diagnosis when primary adrenal insufficiency is suspected. Treatment consists of glucocorticoid and mineralocorticoid replacement. Primary adrenal insufficiency is a 'master of disguise'. Unexplained syncope, vomiting, weight loss or hypoglycemia should prompt suspicion of this disease.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results